公开(公告)号：US10697969B2

公开(公告)日：2020-06-30

申请号：US15192522

申请日：2016-06-24

Applicant: MED-LIFE DISCOVERIES LP

Inventor： Shawn Ritchie ,  Dayan Goodenowe

IPC: G01N33/48 ,  G01N33/50 ,  G01N33/574 ,  G01N33/82

Abstract: The present invention relates to the diagnosis of colorectal and ovarian cancers (CRC and OC, respectively). The present invention describes the relationship between endogenous small molecules and CRC or OC. Specifically, the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E isoforms and related metabolites. The present invention also relates to diagnostic markers identified in said method. The present invention relates to the underlying case and pre-symptomatic phases of CRC, the diagnosis of various stages and severity of CRC, the early detection of CRC, monitoring and diagnosing the effect of therapy on CRC and OC health states.

公开(公告)号：US20190004049A1

公开(公告)日：2019-01-03

申请号：US16027958

申请日：2018-07-05

Applicant: MED-LIFE DISCOVERIES LP

Inventor： Elodie Pastural ,  Shawn Ritchie

IPC: G01N33/574 ,  G01N33/92

Abstract: Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.

公开(公告)号：US10656155B2

公开(公告)日：2020-05-19

申请号：US16027958

申请日：2018-07-05

Applicant: MED-LIFE DISCOVERIES LP

Inventor： Elodie Pastural ,  Shawn Ritchie

IPC: G01N33/574 ,  G01N33/92

Abstract: Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.

公开(公告)号：US11079385B2

公开(公告)日：2021-08-03

申请号：US16830038

申请日：2020-03-25

Applicant: MED-LIFE DISCOVERIES LP

Inventor： Elodie Pastural ,  Shawn Ritchie

IPC: G01N33/574 ,  G01N33/92

Abstract: Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.

公开(公告)号：US20210033614A1

公开(公告)日：2021-02-04

申请号：US16830038

申请日：2020-03-25

Applicant: MED-LIFE DISCOVERIES LP

Inventor： Elodie Pastural ,  Shawn Ritchie

IPC: G01N33/574 ,  G01N33/92

Abstract: Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.